Business Weekly have published an article about the strong interest from global investors in Healx’s upcoming Series A funding round:
“Founder and CEO Tim Guilliams tells Business Weekly that the company already has interest from science & technology investors in London, Silicon Valley, Germany and Japan.”
The article also covers the appointment of Shaun Grady, a leading business development executive, at AstraZeneca, to the Healx board of directors:
“Healx’s fundraising effort has been substantially boosted by the recruitment of AstraZeneca’s Shaun Grady to the board. Grady is vice-president business development operations, leading AstraZeneca’s transaction execution, due diligence and alliance and integration management function. This includes late-stage as well as on-market licensing and partnering, M & A, and divestments.”
Read the full article here.